A key achievement of the EPAD project was the establishment of a Longitudinal Cohort Study (LCS) that has screened over 2,000 participants and collected a wide range of cognitive, clinical, neuroimaging and biomarker data to help further the understanding of the early stages of Alzheimer’s disease. The LCS was initiated and the first participant screened in May 2016. Screening into the LCS was stopped on 29 February 2020. Although the LCS is no longer following up participants, it provides an ongoing legacy through open access to data and a vast range of possibilities for sample access.
The current EPAD database is open-access, ensuring the use of the data for the Alzheimer’s disease research community worldwide. To access the data, you will need to make an online request via the EPAD website. For more information about the EPAD data and samples and how to apply, visit the new webpage: http://ep-ad.org/open-access-data/overview/ The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.
